Bolt Biotherapeutics Logo
US0977022039
A419U9

Bolt Biotherapeutics

Forecast

The analysts' average price target is €3.64 (-21.04%). The median is €3.64 (-21.04%).

Buy
  3
Hold
  5
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2014, Bolt Biotherapeutics has already paid €0.20 in dividends. The last payout was in July 2014.

Financials

In the last quarter, Bolt Biotherapeutics had revenue of €0 and net profit of -€3.9M

(EUR) September 2026
YoY
Revenue 0 100.00%
Gross profit 0 100.00%
Net profit -3.9M 35.87%
EBITDA -3.85M 34.15%

Fundamentals

Metric Value
Market capitalization
€12.01M
Number of shares
2.61M
52-week high/low
€7.08 - €2.82
Dividends No
Beta
1.01
P/E ratio
-0.35
PEG ratio
0.01
P/B ratio
1.16
P/S ratio
5.21

Company profile

Name
Bolt Biotherapeutics
CEO
William Quinn
Headquarters Redwood City, ca
USA
Website
Sector
Materials
Industry
Chemicals
Employees 23
🍪

Parqet  uses cookies. Learn more